Company Overview of kaleo, Inc.
kaleo, Inc., a pharmaceutical company, is engaged in the development and commercialization of various pharmaceuticals for severe allergic reactions and other therapeutic areas. It offers epinephrine auto-injectors. kaleo, Inc. was formerly known as Intelliject, Inc. and changed its name to kaleo, Inc. The company was incorporated in 2008 and is based in Richmond, Virginia.
111 Virginia Street
Richmond, VA 23219
Founded in 2008
Key Executives for kaleo, Inc.
Co-Founder and Vice President of Product Development
Compensation as of Fiscal Year 2013.
kaleo, Inc. Key Developments
Kaleo Announces $150 Million Debt Financing to Support Commercialization of EVZIO(TM)
Apr 7 14
Kaleo announced that it has entered into a $150 million debt facility with PDL BioPharma to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first product (Auvi-Q(TM) in the US and Allerject(TM) in Canada) and a portion of the net sales on its second product (EVZIO(TM)). Once the note is repaid, kaleo will resume receiving 100% of all product royalties and net sales. The funds will enable kaleo to support the commercialization of EVZIO, to invest in the development of pipeline products and repay existing debt. EVZIO is intended for the emergency treatment of known or suspected opioid overdose, as manifested by life-threatening respiratory depression. Kaleo is a pioneer in life saving products that provide for peace of mind that patients can carry in their pockets. Kaleo products are designed to become part of a patient's everyday life - always there, but invisible until needed. The products are simple to use and use voice and visual cues to assist a patient through the correct drug administration process.
U.S. Food and Drug Administration Approves Kaleo's EVZIO for the Emergency Treatment of Opioid Overdose
Apr 3 14
Kaleo announced that the U.S. Food and Drug Administration (FDA) has approved EVZIO(TM) (naloxone hydrochloride injection) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is the first and only naloxone auto-injector intended to be available for immediate administration by family members or caregivers for suspected opioid overdose in settings where opioids may be present. Opioids are part of a class of pain medications that work by binding to receptors in the brain that affect the body's perception of pain, and can cause fatal overdose when the amount of drug in the body is too high. Opioids are used to treat pain associated with a variety of acute and chronic medical conditions. According to the Institute of Medicine, chronic pain affects about 100 million American adults -- more than the total affected by heart disease, cancer and diabetes combined.(3) More than 16,000 Americans die each year from prescription opioid overdose, and accidental drug poisoning has surpassed automobile collisions as the leading cause of accidental death in the U.S., driven largely by prescription opioids. Naloxone, the active ingredient in EVZIO, has been used for more than 40 years for reversal of respiratory depression due to opioid overdose, but has been primarily used by emergency medical services, other medical professionals and in limited naloxone distribution programs.
kaleo, Inc. - Special Call
Apr 3 14
To discuss the U.S. Food and Drug Administration approval of EVZIO for emergency treatment of opioid overdose
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|